Who are we & what's our mission

“Personalized medicine requires fast and accurate diagnostic tests. A correct sample is key to the accuracy of the test result.  Colli-Pee TM is a smart medical device that helps to collect a urine sample in an easy non-invasive and first time right way.  This is beneficial to diagnostic values an lowers the barrier for providing the right medical care in specific target groups.”

Geert Maertens, PhD

CSO Biocartis & Member Scientific Board Novosanis

“VAX-ID… a new, safe, easy to use and accurate intradermal injection device – all you need to guarantee intradermal administration”

Prof Dr Pierre Van Damme

Chairman Board of Directors, Chairman SAB VAX-ID

Who are we & what's our mission

Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests, drug delivery and overall patient’s comfort.

We are a Belgian, award-winning, ISO13485 certified medical device company active in the field of infectious diseases and oncology in the areas of prevention, detection and treatment.

Novosanis prospers in user-friendly and clever medical devices meeting all regulatory and quality requirements, solutions that can improve the accuracy and standardization of the diagnostic test and drug delivery while making the handling easier, more consistent and more comfortable for the person.

We have two device platforms in portfolio: VAX-ID™ is a patented and proven platform of injection devices suited for accurate drug delivery of e.g. therapeutic, prophylactic and allergy vaccines in the dermal layer of the skin and Colli-Pee™ is a patented and CE-marked sampling device suited for standardized and guaranteed collection of first-void urine (first 20ml of the urine flow) allowing improved detection of infectious diseases and early stage cancer. Colli-Pee™ is in a commercial stage.

What we've been up to

Recent Study

Aim: Performance of a new first-void collection device, Colli-Pee

  • Group A: 32 women, positive for HPV16 and/or 18 at earlier testing (HPV DNA on cervical samples).
  • Group B: 155 healthy volunteers (50 men, 105 women), HPV status unknown.
  • Detection of hDNA and HPV DNA in (first void) urine collected using Colli-Pee™ (Novosanis) and Multi-Collect™ (Abbott).

Conclusion: In women, urine collected using the Colli-Pee™device yielded a higher number of copies of hDNA and HPV DNA compared to the Abbott Multi-Collect™ system.

Come and talk to us

Novosanis NV | +32 3 485 50 16 | welcome@novosanis.comBijkhoevelaan 32c, 2110 Wijnegem | Belgium